Nat Commun:在膀胱癌进展中c-Met激活能够引起TGFβ受体调控网络的建立

2019-10-19 AlexYang MedSci原创

肌肉浸润性膀胱癌的治疗仍旧是一个很大的临床挑战。异常的HGF/c-MET上调和激活在膀胱癌中总是出现并且与癌症恶化和浸润相关。然而,HGF/c-MET调节的浸润的潜在机制在膀胱癌中仍旧未知。作为负调控回路的一部分,SMAD7能够与SMURF2结合靶向TGFβ受体使其降解。在这些条件下,SMAD7可以通过干扰SMURF2分子内的相互作用起到SMURF2拮抗剂的作用。在他们的研究中,研究人员阐释了HG

肌肉浸润性膀胱癌的治疗仍旧是一个很大的临床挑战。异常的HGF/c-MET上调和激活在膀胱癌中总是出现并且与癌症恶化和浸润相关。然而,HGF/c-MET调节的浸润的潜在机制在膀胱癌中仍旧未知。

作为负调控回路的一部分,SMAD7能够与SMURF2结合靶向TGFβ受体使其降解。在这些条件下,SMAD7可以通过干扰SMURF2分子内的相互作用起到SMURF2拮抗剂的作用。在他们的研究中,研究人员阐释了HGF能够通过c-SRC调节的SMURF2磷酸化来刺激TGFβ信号,从而导致SMAD7结合功能的丧失,并增强SMURF2 C2-HECT的互作。HGF引起的TGFβ途径的上调能够导致TGFβ调节的EMT和浸润。体内试验表明,TGFβ受体抑制剂能够阻止膀胱癌的浸润。更多的是,研究人员探索了TGFβ和MEK抑制剂的组合比例来进行高等级非肌肉浸润膀胱癌的治疗。

原始出处:

Wen Jing Sim, Prasanna Vasudevan Iyengar, Dilraj Lama et al. c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression. Nat Commun. 25 Sep 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087612, encodeId=1e1b208e61224, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Dec 01 01:09:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722971, encodeId=93b71e229716d, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3877, encryptionId=196d38e720, topicName=c-Met)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=805733331422, createdName=天堂的云, createdTime=Sat May 02 07:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035896, encodeId=afb5203589623, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon May 04 12:09:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035814, encodeId=d9e1203581496, content=<a href='/topic/show?id=3b891e356fc' target=_blank style='color:#2F92EE;'>#TGFβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17356, encryptionId=3b891e356fc, topicName=TGFβ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jun 23 11:09:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883934, encodeId=897118839349f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 03 17:09:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896566, encodeId=5b85189656601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 26 03:09:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009977, encodeId=481c20099e7b0, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Mar 09 21:09:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039953, encodeId=ac7f103995373, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Oct 19 12:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
    2019-12-01 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087612, encodeId=1e1b208e61224, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Dec 01 01:09:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722971, encodeId=93b71e229716d, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3877, encryptionId=196d38e720, topicName=c-Met)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=805733331422, createdName=天堂的云, createdTime=Sat May 02 07:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035896, encodeId=afb5203589623, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon May 04 12:09:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035814, encodeId=d9e1203581496, content=<a href='/topic/show?id=3b891e356fc' target=_blank style='color:#2F92EE;'>#TGFβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17356, encryptionId=3b891e356fc, topicName=TGFβ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jun 23 11:09:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883934, encodeId=897118839349f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 03 17:09:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896566, encodeId=5b85189656601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 26 03:09:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009977, encodeId=481c20099e7b0, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Mar 09 21:09:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039953, encodeId=ac7f103995373, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Oct 19 12:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087612, encodeId=1e1b208e61224, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Dec 01 01:09:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722971, encodeId=93b71e229716d, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3877, encryptionId=196d38e720, topicName=c-Met)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=805733331422, createdName=天堂的云, createdTime=Sat May 02 07:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035896, encodeId=afb5203589623, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon May 04 12:09:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035814, encodeId=d9e1203581496, content=<a href='/topic/show?id=3b891e356fc' target=_blank style='color:#2F92EE;'>#TGFβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17356, encryptionId=3b891e356fc, topicName=TGFβ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jun 23 11:09:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883934, encodeId=897118839349f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 03 17:09:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896566, encodeId=5b85189656601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 26 03:09:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009977, encodeId=481c20099e7b0, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Mar 09 21:09:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039953, encodeId=ac7f103995373, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Oct 19 12:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
    2020-05-04 changhe713
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087612, encodeId=1e1b208e61224, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Dec 01 01:09:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722971, encodeId=93b71e229716d, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3877, encryptionId=196d38e720, topicName=c-Met)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=805733331422, createdName=天堂的云, createdTime=Sat May 02 07:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035896, encodeId=afb5203589623, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon May 04 12:09:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035814, encodeId=d9e1203581496, content=<a href='/topic/show?id=3b891e356fc' target=_blank style='color:#2F92EE;'>#TGFβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17356, encryptionId=3b891e356fc, topicName=TGFβ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jun 23 11:09:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883934, encodeId=897118839349f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 03 17:09:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896566, encodeId=5b85189656601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 26 03:09:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009977, encodeId=481c20099e7b0, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Mar 09 21:09:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039953, encodeId=ac7f103995373, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Oct 19 12:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
    2020-06-23 yuanming7
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087612, encodeId=1e1b208e61224, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Dec 01 01:09:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722971, encodeId=93b71e229716d, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3877, encryptionId=196d38e720, topicName=c-Met)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=805733331422, createdName=天堂的云, createdTime=Sat May 02 07:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035896, encodeId=afb5203589623, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon May 04 12:09:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035814, encodeId=d9e1203581496, content=<a href='/topic/show?id=3b891e356fc' target=_blank style='color:#2F92EE;'>#TGFβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17356, encryptionId=3b891e356fc, topicName=TGFβ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jun 23 11:09:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883934, encodeId=897118839349f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 03 17:09:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896566, encodeId=5b85189656601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 26 03:09:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009977, encodeId=481c20099e7b0, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Mar 09 21:09:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039953, encodeId=ac7f103995373, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Oct 19 12:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
    2020-06-03 liye789132251
  6. [GetPortalCommentsPageByObjectIdResponse(id=2087612, encodeId=1e1b208e61224, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Dec 01 01:09:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722971, encodeId=93b71e229716d, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3877, encryptionId=196d38e720, topicName=c-Met)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=805733331422, createdName=天堂的云, createdTime=Sat May 02 07:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035896, encodeId=afb5203589623, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon May 04 12:09:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035814, encodeId=d9e1203581496, content=<a href='/topic/show?id=3b891e356fc' target=_blank style='color:#2F92EE;'>#TGFβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17356, encryptionId=3b891e356fc, topicName=TGFβ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jun 23 11:09:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883934, encodeId=897118839349f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 03 17:09:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896566, encodeId=5b85189656601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 26 03:09:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009977, encodeId=481c20099e7b0, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Mar 09 21:09:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039953, encodeId=ac7f103995373, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Oct 19 12:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
    2020-03-26 一闲
  7. [GetPortalCommentsPageByObjectIdResponse(id=2087612, encodeId=1e1b208e61224, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Dec 01 01:09:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722971, encodeId=93b71e229716d, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3877, encryptionId=196d38e720, topicName=c-Met)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=805733331422, createdName=天堂的云, createdTime=Sat May 02 07:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035896, encodeId=afb5203589623, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon May 04 12:09:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035814, encodeId=d9e1203581496, content=<a href='/topic/show?id=3b891e356fc' target=_blank style='color:#2F92EE;'>#TGFβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17356, encryptionId=3b891e356fc, topicName=TGFβ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jun 23 11:09:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883934, encodeId=897118839349f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 03 17:09:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896566, encodeId=5b85189656601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 26 03:09:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009977, encodeId=481c20099e7b0, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Mar 09 21:09:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039953, encodeId=ac7f103995373, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Oct 19 12:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2087612, encodeId=1e1b208e61224, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Dec 01 01:09:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722971, encodeId=93b71e229716d, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3877, encryptionId=196d38e720, topicName=c-Met)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=805733331422, createdName=天堂的云, createdTime=Sat May 02 07:09:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035896, encodeId=afb5203589623, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon May 04 12:09:00 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035814, encodeId=d9e1203581496, content=<a href='/topic/show?id=3b891e356fc' target=_blank style='color:#2F92EE;'>#TGFβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17356, encryptionId=3b891e356fc, topicName=TGFβ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jun 23 11:09:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883934, encodeId=897118839349f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 03 17:09:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896566, encodeId=5b85189656601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 26 03:09:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009977, encodeId=481c20099e7b0, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Mar 09 21:09:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039953, encodeId=ac7f103995373, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Oct 19 12:09:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
    2019-10-19 留走人康

    膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效

    0

相关资讯

CAN04在膀胱癌中的阳性临床前数据

Cantargia近日公布了CAN04的阳性临床前数据。大约80%的膀胱癌患者的肿瘤细胞上检测到IL1RAP(CAN04的分子靶标),Cantargia的抗体CAN04能够以高亲和力结合IL1RAP,并通过抗体依赖性细胞毒性和阻断白细胞介素1信号传导起作用。

2019 ESMO:PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效

​罗氏Genentech分公司公布了将Tecentriq(atezolizumab)与铂类化疗相结合用于以前未经治疗晚期膀胱癌患者的III期临床试验阳性结果。

2019 ESMO:癌症新闻大爆炸

在欧美裁员之后,赛诺菲在日本的规模正在缩小。大型制药公司的大多数首席执行官都有自己的中文名字,以新方式表明他们对世界第二大药品市场的关心。在今年的欧洲医学肿瘤学会(ESMO)年会上,Astellas和Seattle Genetics公布了抗体-药物结合物的积极成果,默克公司和Eisai详细介绍了Keytruda-Lenvima组合获胜和Chi-Med宣传VEGFR抑制剂surufatinib的神经

Cell Death & Disease:ERα调节的circ_0023642和miR-490-5p信号变化能够抑制膀胱癌浸润

流行病学研究表明了膀胱癌(BCa)在不同性别中的发生率和预后具有明显差异。之前的研究表明了雌激素受体α(ERα)在BCa中具有保护性作用。然而,ERα通过怎样的机制来调节BCa的恶化仍旧需要进一步的阐释。最近,有研究人员探索了ERα通过调控circRNA水平来抑制BCa浸润的机制。研究发现,ERα可以减少circ_0023642表达来抑制BCa浸润。染色质免疫沉淀(ChIP)和双荧光素试验阐释了E

膀胱癌OR膀胱炎!

患者 男,41岁,右侧腰部胀痛不适1周余,伴尿频,间断性肉眼血尿

Oncogene:雄激素二氢睾酮能够促进膀胱癌核AR阴性细胞浸润

虽然雄激素可能通过核雄激素受体(nAR)来促进膀胱癌(BCa)的恶化,雄激素对肌肉浸润性BCa(包含了将近80%的nAR阴性细胞)的影响仍旧不清楚。最近,有研究人员为了解析雄激素对这些nAR阴性肌肉浸润性BCa的潜在影响,他们发现了雄激素二氢睾酮(DHT)可能通过一个新的膜AR(mAR-SLC39A9)来增加nAR阴性BCa细胞的迁移和浸润。机制解析阐释了DHT/mAR-SLC39A9可能通过改变